1. Home
  2. MLEC vs PMN Comparison

MLEC vs PMN Comparison

Compare MLEC & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moolec Science SA

MLEC

Moolec Science SA

N/A

Current Price

$6.00

Market Cap

5.0M

Sector

Finance

ML Signal

N/A

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

N/A

Current Price

$12.96

Market Cap

131.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MLEC
PMN
Founded
2008
2004
Country
Cayman Islands
Canada
Employees
N/A
N/A
Industry
Blank Checks
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
131.5M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
MLEC
PMN
Price
$6.00
$12.96
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$42.67
AVG Volume (30 Days)
17.3K
33.8K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.42
N/A
Revenue Next Year
$30.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.29
52 Week High
$23.22
$27.40

Technical Indicators

Market Signals
Indicator
MLEC
PMN
Relative Strength Index (RSI) 44.30 44.22
Support Level $5.41 $12.89
Resistance Level $9.08 $14.77
Average True Range (ATR) 0.55 1.21
MACD 0.00 -0.10
Stochastic Oscillator 23.39 21.36

Price Performance

Historical Comparison
MLEC
PMN

About MLEC Moolec Science SA

Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: